HICA Alpha-Hydroxyisocaproic.

Leucine is transaminated to alpha-ketoisocaproate, which is then reduced to alpha-hydroxyisocaproic acid, so HICA is a direct downstream leucine metabolite. Dosing leucine expands the pool HICA is made from.

A BCAA blend supplies the leucine that feeds the keto acid pool HICA comes from, and the valine and isoleucine in it compete for the same transaminase and dehydrogenase enzymes.

HMB and HICA are two fates of the same alpha-ketoisocaproate intermediate, one by oxidation and the other by reduction. A formula carrying both is doubling on one pathway rather than covering two.

Branched chain aminotransferase requires pyridoxal-5-phosphate to convert leucine into the keto acid that becomes HICA. Without adequate B6 the upstream step that supplies the pathway runs slower.

The branched chain ketoacid dehydrogenase complex uses thiamine pyrophosphate to oxidise alpha-ketoisocaproate, the fate that competes with reduction to HICA. Thiamine status shifts how the shared keto acid pool is partitioned.

Methylcrotonyl-CoA carboxylase, a biotin-dependent enzyme, sits further down the leucine catabolic route that shares its opening steps with HICA formation. Biotin status affects flux through that shared branch.

Whey is the densest common leucine source, so it enlarges the substrate pool that feeds keto acid and HICA formation while independently supplying amino acids for protein synthesis.

Creatine raises intramuscular phosphocreatine and supports repeated high-intensity efforts, an effect that has nothing to do with amino-acid metabolism. HICA sits on the leucine catabolic route and is studied for its influence on protein balance. The two occupy different mechanisms so they are not redundant, but no combination trial has been done and the pairing rests on formulation logic.

All three branched-chain amino acids are transaminated by the same aminotransferase and then decarboxylated by the same dehydrogenase complex. HICA is a downstream reduction product of the leucine-derived keto acid on that route. Loading one branched-chain amino acid heavily influences flux for the others, which is the standard reason they are dosed as a set rather than singly.

A leucine metabolite cannot build tissue on its own; net protein accretion needs the full complement of amino acids from dietary protein. Casein digests slowly and sustains circulating amino acids over hours. Where total protein intake is already adequate, adding a metabolite has less room to change anything, and that is the honest limit on this pairing.

Carnosine loading addresses acid accumulation during high-intensity work, a mechanism unrelated to amino-acid catabolism. HICA is positioned around recovery and protein turnover. The rationale for stacking them is that they act on different limits of the same training session, and no study has tested the combination.

Bicarbonate works outside the muscle cell, helping export protons generated during intense work. HICA acts on protein metabolism, so the two do not overlap. Digestive tolerance is the practical constraint on bicarbonate, not any interaction with HICA.

When leucine is transaminated, the amino group is transferred to alpha-ketoglutarate to form glutamate, which is a step on the way to glutamine. Glutamine efflux is how skeletal muscle exports nitrogen. The connection is metabolic and well characterised; what it means for a training outcome when both are supplemented has not been tested.

EPA and DHA incorporate into muscle membrane phospholipids over weeks and have been studied for their influence on protein synthesis signalling. HICA operates on the amino-acid side of the same regulatory system. The two are mechanistically separate and untested together, so the row is a formulation rationale at low confidence.

Taurine's roles in muscle sit in contractile calcium handling and cell volume regulation, not in protein turnover. It is a common companion in recovery blends alongside amino-acid derivatives. No combination data support the pairing, which is why it is marked Early.

Calcium alpha-hydroxyisocaproate contributes calcium to the serving, and calcium interferes with non-heme iron uptake when the two are taken together. Anyone dosing iron for iron status should separate it from a calcium-salt HICA product by a couple of hours. The interaction is with the counter-ion, not with the hydroxy acid.